Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | C379R |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR1 C379R (corresponds to C381R in the canonical isoform) lies within the transmembrane domain of the Fgfr1 protein (PMID: 26272615). C379R results in a gain of function, as demonstrated by constitutive Fgfr1 activity in a luciferase assay and increased Erk1/2 phosphorylation in cell culture (PMID: 26272615). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 act mut FGFR1 C379R |
Transcript | NM_015850.4 |
gDNA | chr8:g.38419676A>G |
cDNA | c.1135T>C |
Protein | p.C379R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001410922.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013225 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001354369.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_047421569.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_015850.4 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013224 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013225.3 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013224.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013225.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_006716306 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_006716307.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_006716307.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001354369.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001174065 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001354367.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_006716307 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
XM_017013223 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_015850.3 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001174065.1 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_015850 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001354367.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
NM_001174065.2 | chr8:g.38419676A>G | c.1135T>C | p.C379R | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|